MA45888A1 - Inhibiteurs de tyrosine kinase de bruton - Google Patents

Inhibiteurs de tyrosine kinase de bruton

Info

Publication number
MA45888A1
MA45888A1 MA45888A MA45888A MA45888A1 MA 45888 A1 MA45888 A1 MA 45888A1 MA 45888 A MA45888 A MA 45888A MA 45888 A MA45888 A MA 45888A MA 45888 A1 MA45888 A1 MA 45888A1
Authority
MA
Morocco
Prior art keywords
independently
alkyl
hal
fragment
group
Prior art date
Application number
MA45888A
Other languages
English (en)
Inventor
Pavel Andreevich Iakovlev
Aleksey Sergeevich Gavrilov
Pavel Aleksandrovich Aleshunin
Svetlana Leonidovna Gorbunova
Mikhail Vladimirovich Rekharsky
Natalia Vladimirovna Kozhemyakina
Anna Aleksandrovna Kukushkina
Anna Sergeevna Kushakova
Leonid Evgen`Evich Mikhaylov
Alexander Moldavsky
Aleksandra Vladimirovna Popkova
Sergey Aleksandrovich Silonov
Svetlana Sergeevna Smirnova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA45888A1 publication Critical patent/MA45888A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un nouveau composé représenté par la formule i, ou un sel, un solvate ou un stéréoisomère pharmaceutiquement acceptable de celui-ci, dans laquelle : v1 est c ou n, v2 est c(r2) ou n, ainsi si v1 est c alors v2 est n, si v1 est c alors v2 est c(r2), ou si v1 est n alors v2 est c(r2); chaque n, k est indépendamment 0, 1; chaque r2, r11 est indépendamment h, d, hal, cn, nr'r", c(o)nr'r", un alkoxy c1-c6; r3 est h, d, un hydroxy, un alkyle en c(o)c1-c6, un alcényle en c(o)c2-c6 , un alcényle en c(o)c2-c6, un alkyle en c1-c6; r4 est h, hal, cn, conr'r", un hydroxy, un alkyle en c1-c6, un alkoxy c1-c6; l est ch2, nh, o ou une liaison chimique; r1 est choisi dans le groupe de fragments, comprenant : fragment 1, fragment 2, fragment 3 chaque a1, a2, a3, a4 est indépendamment ch, n, chal; chaque a5, a6, a7, a8, a9 est indépendamment c, ch ou n; r5 est h, cn, hal, conr'r", un alkyle en c1-c6, non substitué ou substitué par un ou plusieurs halogènes; chaque r' et r" est indépendamment sélectionné dans le groupe comprenant, h, un alkyle en c1-c6, un cycloalkyle en c1-c6, un aryle; r6 est sélectionné dans le groupe : [formule ii] chaque r7, r8, r9, r10est indépendamment un vinyle, un méthylacétylényle; hal est ci, br, i, f, qui possèdent des propriétés d'un inhibiteur de tyrosine kinase de bruton (btk), la présente invention concerne également des compositions pharmaceutiques contenant lesdits composés, et leur utilisation en tant qu'agents pharmaceutiques dans le traitement de maladies et troubles.
MA45888A 2016-11-18 2017-11-16 Inhibiteurs de tyrosine kinase de bruton MA45888A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662424041P 2016-11-18 2016-11-18
PCT/IB2017/057154 WO2018092047A1 (fr) 2016-11-18 2017-11-16 Inhibiteurs de tyrosine kinase de bruton

Publications (1)

Publication Number Publication Date
MA45888A1 true MA45888A1 (fr) 2020-06-30

Family

ID=60574666

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45888A MA45888A1 (fr) 2016-11-18 2017-11-16 Inhibiteurs de tyrosine kinase de bruton

Country Status (19)

Country Link
US (1) US20190352276A1 (fr)
EP (1) EP3541811A1 (fr)
JP (1) JP2019537611A (fr)
KR (1) KR20190104516A (fr)
CN (1) CN110177781A (fr)
AU (1) AU2017362066A1 (fr)
BR (1) BR112019009945A2 (fr)
CA (1) CA3043297A1 (fr)
CL (1) CL2019001330A1 (fr)
CR (1) CR20190261A (fr)
EA (1) EA201990902A1 (fr)
EC (1) ECSP19043231A (fr)
JO (1) JOP20190113A1 (fr)
MA (1) MA45888A1 (fr)
MX (1) MX2019005706A (fr)
PE (1) PE20191082A1 (fr)
PH (1) PH12019550083A1 (fr)
WO (1) WO2018092047A1 (fr)
ZA (1) ZA201903694B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793566B2 (en) * 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019013562A1 (fr) * 2017-07-12 2019-01-17 주식회사 대웅제약 Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
HRP20240283T1 (hr) * 2019-09-26 2024-05-10 Jumbo Drug Bank Co., Ltd. Derivati 4-fluoro-1h-pirazolo[3,4-c]piridina kao selektivni inhibitori brutonove tirozin kinaze (btk) za liječenje b-staničnih limfoma i autoimunih bolesti
CN114478519B (zh) * 2020-10-23 2024-06-11 励缔(杭州)医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途
WO2022140246A1 (fr) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Procédés et composés destinés à l'autophagie ciblée
WO2022228302A1 (fr) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Composés carboxamides hétéroaromatiques et leur utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010284A (es) * 2007-03-28 2010-01-29 Pharmacyclics Inc Inhibidores de la tirosina-cinasa de bruton.
EP2464647B1 (fr) * 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindoles en tant qe modulateurs du recepteur btk et leur utilisation
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2548877A1 (fr) * 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
CA2881519A1 (fr) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Composes heteroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
US9637486B2 (en) * 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
JP6162904B2 (ja) * 2014-02-03 2017-07-12 カディラ ヘルスケア リミティド 新規複素環式化合物
EP3174539A4 (fr) * 2014-08-01 2017-12-13 Pharmacyclics, LLC Inhibiteurs de la tyrosine kinase de bruton
CA3009669C (fr) * 2016-01-21 2023-08-08 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Inhibiteurs de la tyrosine kinase de bruton
WO2017156495A1 (fr) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Composés et procédés pour moduler la tyrosine kinase de bruton

Also Published As

Publication number Publication date
CR20190261A (es) 2019-09-02
WO2018092047A1 (fr) 2018-05-24
MX2019005706A (es) 2019-07-08
ECSP19043231A (es) 2019-06-30
JOP20190113A1 (ar) 2019-05-15
CA3043297A1 (fr) 2018-05-24
EA201990902A1 (ru) 2019-11-29
EP3541811A1 (fr) 2019-09-25
CN110177781A (zh) 2019-08-27
PH12019550083A1 (en) 2020-03-09
CL2019001330A1 (es) 2019-09-27
ZA201903694B (en) 2021-04-28
JP2019537611A (ja) 2019-12-26
AU2017362066A1 (en) 2019-05-30
KR20190104516A (ko) 2019-09-10
US20190352276A1 (en) 2019-11-21
PE20191082A1 (es) 2019-08-20
BR112019009945A2 (pt) 2019-08-13

Similar Documents

Publication Publication Date Title
MA45888A1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
MX2020011501A (es) Compuestos novedosos.
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
EP4371562A3 (fr) Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
MA49127B1 (fr) Dérivés d'indole n-substitués
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MX2021011389A (es) Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos.
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
EA202191349A1 (ru) 1,3,4-оксадиазолон и фармацевтический препарат
US9980936B2 (en) BH4 antagonists and methods related thereto
MA50036A (fr) Composés de fluoropipéridine utilisés en tant qu'antagonistes purs du récepteur 5-ht6
MA53138B1 (fr) Dérivés de 3-(5-hydroxy-1-oxoisoindoline-2-yl)pipéridine-2,6-dione et leur utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2)
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19